Publications by authors named "Isabel De la Morena"
Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
Diego Benavent Santiago Muñoz-Fernández Isabel De la Morena Antonio Fernández-Nebro Judith Marín-Corral
Ther Adv Musculoskelet Dis
December 2023
Article Synopsis
- Spondyloarthritis (SpA) is a group of related diseases, including axSpA and psoriatic arthritis (PsA), but there isn't much real-world information about them.
- The study aimed to look into the characteristics and treatment of axSpA and PsA patients using data from hospitals and fancy computer technology.
- Out of 887,735 patients, 758 were chosen for the study, revealing that many didn't have clear disease activity scores, which are important for understanding how serious their condition is.
Introduction: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinumab, a biologic disease-modifying antirheumatic drug (bDMARD), has extensive clinical evidence of efficacy and safety in the treatment of PsA but data in clinical practice are still limited. This study aims to provide real-world evidence on secukinumab use, effectiveness, and persistence in PsA.
View Article and Find Full Text PDFBackground: Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials.
View Article and Find Full Text PDF